Haemophilia management programme: Transformation during COVID-19

Simple item page
dc.contributor.authorSait, Haseenaen_US
dc.contributor.authorSajjan, Shruti M.en_US
dc.contributor.authorPhadke, Shubha R.en_US
dc.date.accessioned2023-08-19T04:52:10Z
dc.date.available2023-08-19T04:52:10Z
dc.date.issued2022-06
dc.description.abstractBackground & objectives: Haemophilia is a debilitating bleeding disorder with significant comorbidities affecting the quality of life. In India, the management of these individuals is still limited to on-demand institutional treatment with coagulant factors. In this study, we highlighted the problems faced by these patients in the COVID-19 period due to nationwide lockdown. Methods: A retrospective study was done to ascertain the trend in the number of patients with haemophilia A and B visiting the hospital, those succumbing to haemophilic complications and indications for factor requirement in the pre-COVID (October 2019-March 2020) and during the COVID-19 period (April-September 2020). Representative cases with unusual complications were described along with significant challenges faced in providing standard care of treatment to these individuals due to the COVID-19 pandemic. Results: A total of 818 and 162 individuals with haemophilia A and B, respectively, were registered with the department. The overall number of patient visits to the hospital significantly reduced from an average of 6.9 outpatient department (OPD) visits per patient in the pre-COVID-19 period to an average of 3.9 OPD visits per patient and admissions reduced to 50 per cent during the COVID-19 period. This led to a reduction in utilization of factors VIII and IX except VIIa for haemophilia with inhibitors. There was no factor utilization for elective surgeries during the COVID-19 period. A total of eight patients succumbed to haemophilia-related complications during the COVID-19 period due to delay in reaching the hospital. The challenges faced in the management of three cases with musculoskeletal bleeds, one case with scrotal haematoma and one with haemothorax during the COVID-19 period were also highlighted. Interpretation & conclusions: COVID-19 pandemic has unveiled the need for on-demand home treatment with coagulant factors and has also brought to light the existing need for primary prophylaxis, especially for younger individuals with haemophilia.en_US
dc.identifier.affiliationsDepartment of Medical Genetics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, Indiaen_US
dc.identifier.citationSait Haseena, Sajjan Shruti M., Phadke Shubha R.. Haemophilia management programme: Transformation during COVID-19 . Indian Journal of Medical Research. 2022 Jun; 155(5-6): 472–477en_US
dc.identifier.issn0971-5916
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/223616
dc.languageenen_US
dc.publisherWolters Kluwer – Medknowen_US
dc.relation.issuenumber5-6en_US
dc.relation.volume155en_US
dc.source.urihttps://doi.org/10.4103/ijmr.ijmr_1941_21en_US
dc.subjectBleeding disorderen_US
dc.subjectcoagulant factoren_US
dc.subjectCOVID-19en_US
dc.subjectemicizumaben_US
dc.subjecthaemophiliaen_US
dc.subjectmanagementen_US
dc.titleHaemophilia management programme: Transformation during COVID-19en_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IJMR2022v155n5-6p472.pdf
Size:
1.04 MB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Medical Research